Lipocine Inc. Presents at H.C. Wainwright Investor Conference

What Happened

• Lipocine, Inc. filed a Form 8-K on September 16, 2026, reporting that it presented at the H.C. Wainwright 28th Annual Global Investor Conference held September 14–16, 2026 in New York City.
• The company furnished its conference presentation as Exhibit 99.1 to the 8-K. The filing does not report earnings, revenue figures, executive changes, mergers, or other financial statements.

Key Details

• Filing date: September 16, 2026 (Form 8-K, Item 8.01 Other Events).
• Event: H.C. Wainwright 28th Annual Global Investor Conference, Sept 14–16, 2026, New York City.
• Exhibit furnished: Presentation included as Exhibit 99.1 to the 8-K.
• No quarterly results, CEO/CFO changes, or material financial disclosures were reported in this filing.

Why It Matters

• This 8-K provides investors with Lipocine’s recent investor presentation and related company updates shared at the conference. Reviewing Exhibit 99.1 is the best way to see details disclosed at the event (pipeline, strategy, or corporate overview).
• Because the filing is an informational disclosure under Item 8.01 and contains no earnings or executive-change data, it does not replace formal financial reports or SEC filings that report revenue, quarterly results, or material corporate actions. Investors seeking material financial or corporate-change information should look for future 8-Ks or periodic reports.